Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05099588
Other study ID # 280/15-04-2020
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2020
Est. completion date January 15, 2023

Study information

Verified date February 2023
Source Aristotle University Of Thessaloniki
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A prospective observational study of the incidence of treatment-requiring ROP (TR-ROP), at a national level, in Greece.


Description:

The purpose of this observational study is to prospectively collect data on ROP cases necessitating treatment at a national level. Each and every ROP screening unit in Greece (collaborating centers) report their new TR-ROP cases, their demographics and treatment characteristics, monthly, for a 12-month period. A reminder email is sent to avoid under-reporting due to neglect. Data are collected by the Responsible Party and will be analyzed together with national registry data on all preterm births in the same 12-month period.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date January 15, 2023
Est. primary completion date January 15, 2023
Accepts healthy volunteers No
Gender All
Age group 30 Weeks to 50 Weeks
Eligibility Inclusion Criteria: - Preterm infants undergoing screening for ROP, who developed TR-ROP and were treated for ROP in one or two eyes. Exclusion Criteria: - None.

Study Design


Intervention

Other:
Other: observational study
Observational study

Locations

Country Name City State
Greece Papageorgiou General Hospital Thessaloníki

Sponsors (13)

Lead Sponsor Collaborator
Aristotle University Of Thessaloniki Agia Sofia Children's Hospital, Athens, Greece, Athens General Children's Hospital "Pan.&Aglaia Kyriakou", Athens, Greece, Attikon General Hospital, Athens, Greece, General University Hospital of Alexandroupoli, Greece, General University Hospital of Heraklion, Greece, General University Hospital of Ioannina, Greece, General University Hospital of Larisa, Greece, General University Hospital of Patras, Greece, Iaso Neonatology Clinic, Athens, Greece, Ippokratio General Hospital, Thessaloniki, Greece, REA Maternity Hospital, Athens, Greece, Venizeleio General Hospital of Heraklion, Greece

Country where clinical trial is conducted

Greece, 

References & Publications (1)

Adams GG, Bunce C, Xing W, Butler L, Long V, Reddy A, Dahlmann-Noor AH. Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk. BMJ Open. 2017 Mar 21;7(3):e013366. doi: 10.1136/bmjopen-2016-013366. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of treatment-requiring ROP (TR-ROP) in Greece During the study period (1 year, prospectively)
Secondary The mean gestational age and birth weight of infants treated for ROP in Greece During the study period (1 year, prospectively)
Secondary The rate of participants treated with laser photocoagulation versus anti-VEGF injection During the study period (1 year, prospectively)
Secondary The failure and recurrence rate of applied treatments for ROP During the follow-up period (6 months from treatment, prospectively)
See also
  Status Clinical Trial Phase
Completed NCT05043077 - Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening Phase 4
Completed NCT04838665 - Changes in Vital Signs and Pupil Diameter Related to Pharmacologic Mydriasis in Premature Infants: A Randomized Double Blind Clinical Study Phase 4
Completed NCT04408807 - Stress Induced by Screening for Retinopathy of Prematurity - Should Speculum and Indentation Rather be Avoided N/A
Recruiting NCT03083431 - Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity Phase 2
Enrolling by invitation NCT04985448 - Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data
Recruiting NCT02090322 - Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1 N/A
Completed NCT00872664 - Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids N/A
Unknown status NCT00254176 - Cysteine Supplementation in Critically Ill Neonates Phase 2/Phase 3
Completed NCT06452524 - Prematurity and Ophthalmological Changes
Completed NCT04101721 - Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity Phase 3
Enrolling by invitation NCT02050971 - Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates Phase 1
Terminated NCT01335113 - A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity
Active, not recruiting NCT00027222 - The Early Treatment for Retinopathy of Prematurity Study (ETROP) Phase 2/Phase 3
Recruiting NCT06109285 - Validation of i-ROP DL to Detect More Than Mild ROP N/A
Completed NCT02014454 - Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature Phase 2
Completed NCT01861470 - REDEXAM - Reducing Painful Eye Examinations in Preterm Infants N/A
Terminated NCT00634972 - Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity Phase 4
Completed NCT05701124 - Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity Phase 3
Completed NCT04092127 - Pain of Premature Babies and RetCam (DOLICAM)
Completed NCT04621136 - PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity Phase 1/Phase 2